Abstract
The clostridial neurotoxins (CNTs) are among the most potent protein toxins known to humans. CNTs include seven serotypes (A~G) of botulinum toxins (BoNTs), which cause botulism, a flaccid paralysis, and tetanus toxin (TeNT), which causes spastic paralysis. BoNTs are classified as category A agent and may be used as potential bioterrorism weapons. On the other hand, the ability of an extremely low dosage of BoNTs (less than 1 ng) to cause reversible partial paralysis upon injection into muscle has turned BoNTs, in particular serotypes A and B, from deadly agents to novel therapeutic agents for treatment of a wide range of clinical conditions associated with involuntary muscle spasm and contractions. In addition to clinical use, they may also be used in cosmetics. Further indications for BoNTs will continue to be developed, although current BoNT therapies have encountered some limitations due to the pharmacological properties of BoNTs, such as their ability to elicit immunoresistance in patients upon periodical injections. This review summarizes the present knowledge of the mechanisms of action of CNTs, with particular focus on the mode of substrate recognition by CNT catalytic domains and knowledge regarding substrate recognition can be utilized to develop novel BoNT products to extend its usefulness in therapeutic interventions and overcome the immunoresistance problems.
Keywords: Botulinum toxins (BoNTs), Clostridial neurotoxins (CNTs), novel therapy development, substrate recognition.
Current Protein & Peptide Science
Title:Clostridial Neurotoxins: Mode of Substrate Recognition and Novel Therapy Development
Volume: 15 Issue: 5
Author(s): Sheng Chen
Affiliation:
Keywords: Botulinum toxins (BoNTs), Clostridial neurotoxins (CNTs), novel therapy development, substrate recognition.
Abstract: The clostridial neurotoxins (CNTs) are among the most potent protein toxins known to humans. CNTs include seven serotypes (A~G) of botulinum toxins (BoNTs), which cause botulism, a flaccid paralysis, and tetanus toxin (TeNT), which causes spastic paralysis. BoNTs are classified as category A agent and may be used as potential bioterrorism weapons. On the other hand, the ability of an extremely low dosage of BoNTs (less than 1 ng) to cause reversible partial paralysis upon injection into muscle has turned BoNTs, in particular serotypes A and B, from deadly agents to novel therapeutic agents for treatment of a wide range of clinical conditions associated with involuntary muscle spasm and contractions. In addition to clinical use, they may also be used in cosmetics. Further indications for BoNTs will continue to be developed, although current BoNT therapies have encountered some limitations due to the pharmacological properties of BoNTs, such as their ability to elicit immunoresistance in patients upon periodical injections. This review summarizes the present knowledge of the mechanisms of action of CNTs, with particular focus on the mode of substrate recognition by CNT catalytic domains and knowledge regarding substrate recognition can be utilized to develop novel BoNT products to extend its usefulness in therapeutic interventions and overcome the immunoresistance problems.
Export Options
About this article
Cite this article as:
Chen Sheng, Clostridial Neurotoxins: Mode of Substrate Recognition and Novel Therapy Development, Current Protein & Peptide Science 2014; 15 (5) . https://dx.doi.org/10.2174/13892037113146660086
DOI https://dx.doi.org/10.2174/13892037113146660086 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
Call for Papers in Thematic Issues
Advancements in Proteomic and Peptidomic Approaches in Cancer Immunotherapy: Unveiling the Immune Microenvironment
The scope of this thematic issue centers on the integration of proteomic and peptidomic technologies into the field of cancer immunotherapy, with a particular emphasis on exploring the tumor immune microenvironment. This issue aims to gather contributions that illustrate the application of these advanced methodologies in unveiling the complex interplay ...read more
Artificial Intelligence for Protein Research
Protein research, essential for understanding biological processes and creating therapeutics, faces challenges due to the intricate nature of protein structures and functions. Traditional methods are limited in exploring the vast protein sequence space efficiently. Artificial intelligence (AI) and machine learning (ML) offer promising solutions by improving predictions and speeding up ...read more
Nutrition and Metabolism in Musculoskeletal Diseases
The musculoskeletal system consists mainly of cartilage, bone, muscles, tendons, connective tissue and ligaments. Balanced metabolism is of vital importance for the homeostasis of the musculoskeletal system. A series of musculoskeletal diseases (for example, sarcopenia, osteoporosis) are resulted from the dysregulated metabolism of the musculoskeletal system. Furthermore, metabolic diseases (such ...read more
Protein Folding, Aggregation and Liquid-Liquid Phase Separation
Protein folding, misfolding and aggregation remain one of the main problems of interdisciplinary science not only because many questions are still open, but also because they are important from the point of view of practical application. Protein aggregation and formation of fibrillar structures, for example, is a hallmark of a ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Roles of Chromatin Remodeling Proteins in Cancer
Current Protein & Peptide Science Astatine-211: Production and Availability
Current Radiopharmaceuticals Co-Enzyme Q10 to Treat Neurological Disorders: Basic Mechanisms, Clinical Outcomes, and Future Research Direction
CNS & Neurological Disorders - Drug Targets Newer Insights in Personalized and Evidence Based Medicine- the Role of MicroRNAs
Current Pharmacogenomics and Personalized Medicine Homocysteine in Neurology: From Endothelium to Neurodegeneration
Current Nutrition & Food Science Emerging Indications for Statins: A Pluripotent Family of Agents with Several Potential Applications
Current Pharmaceutical Design Mutations of Chromatin Structure Regulating Genes in Human Malignancies
Current Protein & Peptide Science Chemical and Bioactive Diversities of the Genus Chaetomium Secondary Metabolites
Mini-Reviews in Medicinal Chemistry Hypoxia-inducible Factor (HIF) in Hormone Signaling During Health and Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Melatonin Attenuates Methamphetamine-Induced Neurotoxicity
Current Pharmaceutical Design Therapeutic Use of Agonists of the Nuclear Receptor PPARγ in Alzheimers Disease
Current Alzheimer Research Preventive and Protective Roles of Dietary Nrf2 Activators Against Central Nervous System Diseases
CNS & Neurological Disorders - Drug Targets Recent Advances in Nanotechnology-Based Drug Delivery Approaches for Alzheimer disease
Current Drug Targets Patent Selections
Recent Patents on DNA & Gene Sequences Gene Therapy Targeting in the Central Nervous System
Current Gene Therapy Computational Models for 5αR Inhibitors for Treatment of Prostate Cancer: Review of Previous Works and Screening of Natural Inhibitors of 5αR2
Current Computer-Aided Drug Design Oncolytic HSV-1 Virotherapy: Clinical Experience and Opportunities for Progress
Current Pharmaceutical Biotechnology Regulation of Insulin Release at Pre-exocytotic Stages of the Secretory Process
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Hypoxic Tumor Microenvironment and Cancer Cell Differentiation
Current Molecular Medicine Treatment of CNS Malignancies with a Recombinant Oncolytic Poliovirus
Drug Design Reviews - Online (Discontinued)